Additionally, there are several studies to screen candidates who could benefit from immunotherapy and/or targeted therapy and investigate the tumor microenvironment and biomarkers of the efficacy of targeted and/or immunotherapy in patients with sarcoma, such as BIOVAS (NCT04072042) (39) and HIFU-UPS (NCT04123535) (40). Here, HMBS is linked to neoplasm.